explore -WSS

explore

author：entertainment 2025-10-01 11:46:49 - browse：715

Since the early days of the pandemic, long Covid has haunted us: Even a mild acute infection might leave you with life-altering consequences. And for many, that has, sadly, turned out to be the case. While research suggests long Covid rates are falling, it still affects millions. In June 2023, 6% of Americans reported experiencing long Covid.

But what if long Covid isn’t the right way to think about what they are going through?

On this episode of the First Opinion Podcast, I spoke with Steven Phillips and Michelle A. Williams, authors of a recent First Opinion essay titled, “Long Covid is a new name for an old syndrome.” Steven is a Global Virus Network board member and vice president for science and strategy at the COVID Collaborative; Michelle is the former dean and current Joan and Julius Jacobson professor of epidemiology and public health at the Harvard T.H. Chan School of Public Health.

“Michelle and I have come up with basically a new paradigm that says long Covid is really an old disease, and the more you do deep dives into the history of chronic fatigue syndrome and post-infectious fatigue syndromes, the more you realize that not only are there similarities, but the level of congruence between the two is strikingly high,” Steven said.

The purpose of this new paradigm is to “break the logjam” of the current long Covid discourse and “to try to provide a framework whereby people would think about long Covid in a different way in a way that would be more productive,” Michelle told me.

We discussed the history of post-infectious disease syndrome, what rethinking long Covid might mean for research, and the ways the health care system fails chronically ill patients.

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, Google Play, or wherever you get your podcasts.

Previous article： New air purifier tech could be key to improving indoor air quality
Next article： Long Covid research funding gets a major boost from NIH

hotspot

WSS

FDA approves world's first CRISPR

Resistance to opioid

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Abbott's new heart device gets FDA advisory panel nod

Congress might make insulin pumps more accessible to the blind

Artificial intelligence use in health care faces greater scrutiny in 2024

hotspot

explore

Wikipedia

DIEP, the 'gold standard' of breast reconstruction, is under threat

Congress might make insulin pumps more accessible to the blind

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Ebola vaccine can save some who are already sick, per new study

Medicare proposal to cover medical devices draws a mixed reaction

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

New air purifier tech could be key to improving indoor air quality

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

Anesthesiologist group: stop taking Ozempic before surgery

Teach medical students about patients with intellectual disabilities

leisure time

Patients' immediate access to test results puts radiologists in a bind

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Tome Biosciences co

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

Artificial intelligence use in health care faces greater scrutiny in 2024

STAT letters to the editor on burnt

explore

hotspot

explore

knowledge